Success Metrics

Clinical Success Rate
100.0%

Based on 20 completed trials

Completion Rate
100%(20/20)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
9
45%
Ph phase_3
4
20%
Ph phase_1
7
35%

Phase Distribution

7

Early Stage

9

Mid Stage

4

Late Stage

Phase Distribution20 total trials
Phase 1Safety & dosage
7(35.0%)
Phase 2Efficacy & side effects
9(45.0%)
Phase 3Large-scale testing
4(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

20 of 20 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

20

all time

Status Distribution
Completed(20)

Detailed Status

Completed20

Development Timeline

Analytics

Development Status

Total Trials
20
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 17 (35.0%)
Phase 29 (45.0%)
Phase 34 (20.0%)

Trials by Status

completed20100%

Recent Activity

Clinical Trials (20)

Showing 20 of 20 trials
NCT00902928Phase 2

A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery

Completed
NCT00994292Phase 2

Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary Syndromes

Completed
NCT01657981Phase 1

A Study to Find Out How YM150 is Absorbed Into and Eliminated From the Body in Healthy Male Subjects

Completed
NCT01655056Phase 1

A Study to Evaluate the Safety and Tolerability of YM150 in Healthy Caucasian and Japanese Male and Female Subjects, and to Assess the Effect That Gender May Have on Its Actions in the Body

Completed
NCT00595426Phase 2

A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement Surgery

Completed
NCT00353678Phase 2

Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)

Completed
NCT01514812Phase 1

A Study to Investigate the Effect of YM150 on the Plasma Concentration of Digoxin in Healthy Subjects

Completed
NCT01514825Phase 1

A Study to Investigate the Plasma Concentration of YM150 After Repeated Administration to Elderly Subjects

Completed
NCT00408239Phase 2

Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement

Completed
NCT00448214Phase 2

Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation

Completed
NCT00938730Phase 2

A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial Fibrillation

Completed
NCT00937820Phase 3

Prevention of Recurrence of Venous Thromboembolism in Patients With a History of Venous Thromboembolism

Completed
NCT01028950Phase 3

YM150 for Prevention of Venous Thromboembolism in Patients With Acute Medical Illness

Completed
NCT00937911Phase 3

Prevention of Venous Thromboembolism in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower Extremities

Completed
NCT00942435Phase 3

A Study to Assess the Effect of YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

Completed
NCT00917254Phase 2

Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery

Completed
NCT00913120Phase 2

Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery

Completed
NCT01125670Phase 1

A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150 Tablet

Completed
NCT01125657Phase 1

A Study to Compare the Pharmacokinetics of YM150 Formulation-A and Formulation-B

Completed
NCT01118559Phase 1

A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150

Completed

All 20 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
20